Nemesis Bioscience

Nemesis Bioscience is developing, and will commercialise, therapeutic agents that will resurrect the antibiotic sensitivity of currently resistant microbial pathogens. These Nemesis symbiotics will both kill pathogenic microorganisms directly and/or make them susceptible to currently existing antibiotics. This will make possible the ability to treat infections and to prophylactically prevent patients acquiring potentially life-threatening resistant pathogens in the first place. Nemesis symbiotics will be administered orally, topically and via dietary supplements. The company has filed initial patent applications on its technologies and therapeutic approaches. More information is available by contacting us directly.